Pfizer Inc. announced Thursday that it will move forward with testing a modified, once-daily version of its weight-loss drug, danuglipron.
The drugmaker said it had considered several options and had chosen danuglipron based on the results of its ongoing pharmacokinetic study.
In December, Pfizer discontinued a twice-daily regimen of danuglipron after study patients struggled with tolerating the drug in a mid-stage study.
"Obesity is a key therapeutic area for Pfizer and the company has a robust pipeline of three clinical candidates and several preclinical candidates," Mikael Dolsten, president of Pfizer Research and Development, said in a statement.
"After a thorough analysis of our previous Phase 2b data and trial design, we believe that with the preferred modified release formulation and optimization of the future trial design, we can advance a competitive oral GLP-1 molecule into studies that enable registration, with the goal of addressing the current and ongoing medical needs of people living with obesity."
Pfizer will need to proceed with large-scale clinical trials to show that the drug is safe and effective and then submit it to the Food and Drug Administration for approval.
During a conference call in June, Albert Bourla, CEO of Pfizer, said, according to CNBC, that GLP-1 drugs are just "scratching the surface of what we're going to see in obesity."
edition
t7 live
